The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

Detailed price information for Cosciens Biopharma Inc (CSCI-T) from The Globe and Mail including charting and trades.

GoodRx (NASDAQ: GDRX), the leading prescription savings platform in the U.S., today announced consumers will soon be able to use Affirm to pay over time for select medications at participating retail ...

India’s pharmaceutical industry is projected to hit $42.9b by 2028 with a compound annual growth rate of 6.3% in local ...

Inversion, a startup developing systems to return cargo from space to Earth, has received a license for its first mission launching in November.

The blue blood of threatened horseshoe crabs contains a chemical essential for testing the safety of vaccines. So these ...

The evolution of Pharma 4.0 integrates advanced technologies, transforming drug development and manufacturing with improved ...

Cobenfy's journey from the lab through regulatory approval is a case study in how America's world-class scientists work to ...

The acquisition of four GHH assets by KELIX Bio significantly enhances the UAE's local life sciences capabilities through ...

To bridge the gap until generic versions become available, Gilead has also committed to supply the product at no profit to ...

and has been granted a new cultivation license by Health Canada. Production is expected to begin in early 2025, marking ...